• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    The advances in immunotherapy for hepatocellular carcinoma

    2020-12-19 04:28:14FanZhangYuminLi
    Hepatoma Research 2020年7期

    Fan Zhang, Yumin Li

    1Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China.

    2Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou 730030, Gansu,China.

    Abstract Hepatocellular carcinoma (HCC) is one of the malignant tumors with higher incidence and mortality worldwide.Recently, significant progress has been made in uncovering immunotherapy in HCC, for instance programmed death-1, cytotoxic T-lymphocyte antigen 4, chimeric antigen receptor T-cell therapy, T cell receptor T cell therapy,dendritic cell vaccine, and cytokine-induced killer cells. This paper reviews the advances in immunotherapy and focuses on the results of many of preclinical studies and clinical trials in the field, as well as some of the promising therapeutic strategies for HCC in the future.

    Keywords: HCC, PD-1, PD-L1, CTLA-4, CAR-T, T cell receptor, DC, CIK

    INTRODUCTION

    Hepatocellular carcinoma (HCC) was predicted to have the sixth highest incidence and the second highest mortality of malignant tumors worldwide in 2018[1]. The risk factors for HCC are closely related with lifestyle,chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, fatty liver disease, and cirrhosis[2-4].The management of HCC involves a multidisciplinary team approach, considering not only the tumor stage and patient complications but also the seriousness of damaged liver function, as most HCC treatments can aggravate the severity of disease[5]. Although surgical resection remains the cornerstone of HCC therapy,limitations are caused by high recurrence rates after surgery because HCC is often diagnosed at advanced stage[6]. Liver transplantation (LT) is the optimal treatment means for early-stage HCC, but limitations of LT are caused by organ shortage, tumor recurrences, and low-ratio eligibility. Comprehensive therapies for advanced HCC patients, such as radiotherapy, chemotherapy, interventional therapy, and targeted therapy,have been developed, but the 5-year survival rate remains low[7].Cancer immunotherapy was selected as its annual breakthrough in Science journal in 2013. Following the advancements of immunotherapy in solid tumors over the last few years, as shown by the results of immune checkpoint inhibitors (ICIs) in lung cancer, renal cell cancer and melanoma[8], in recent years, ICIs with anti-CTLA-4 antibodies and anti-PD-1/PD-1L antibodies have been utilized to treat advanced melanoma[9]. In 2018, because of the achievements in the treatment of cancer with ICIs of CTLA-4 and PD-1/PD-L1, James P.Allison and Tasuku Honjo were awarded the Nobel prize.

    Chimeric antigen receptor T-cell (CAR-T) immunotherapy has become more popular in the last decade as an antitumor therapy. Anti-CD19 CAR-T cell was approved by the FDA for treatment of subjects up to 25 years of age with B-cell acute lymphoblastic leukemia in 2017[10]. This article mainly summarizes the advances in ICIs and cellular immunotherapy for HCC.

    PD-1/PD-L1

    PD-1 is expressed on a subset of thymocytes and is upregulated on activated T cell, B cell, and myeloid cells[11]. Two ligands for PD-1 were identified in 2000 and 2001 and named PD-L1 and programmed death ligand 2 (PD-L2), respectively[12,13]. PD-L1 is mainly expressed on stationary T cells, B cells, DC, and hepatoma cells, while PD-L2 is only expressed on DC and macrophages[14-16]. In theory, the interaction of PD-1 and PD-L1 expressed on immature T cells can interfere with activation. Similarly, if PD-L1 is highly expressed on tumor cell, the ligand receptor interactions between tumor cells and activated T cells triggers the immunosuppressive response, leading to immune tolerance[17]. It provides a theoretical basis for the treatment of PD-L1 in HCC.

    It has been demonstrated that PD-L1 is overexpressed in HCC tissues; however, the results are controversial with respect to PD-L1 as predictive biomarkers for HCC[18]. Several studies have reported that the higher PD-L1 expression on tumor cell in HCC patients were related with worse prognosis and tumor recurrence,and the studies also showed PD-L1 expression on macrophages was associated with favorable survival rate[19-23]. However, two studies suggested that the expression of PD-L1 was not significantly correlated with survival outcomes in HCC[24,25]. Both soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) were prognostic factors with opposite prognostic values for HCC patients, while sPD-1 and sPD-L1 were not significantly related with PD-L1 expression in tumor[26]. However, two studies suggested plasma sPD-1 was associated with HBV activity and increased risk of HCC[27,28].

    I heard the footsteps7 on the sidewalk and the light tap on the wooden door. My lip began to quiver8, opening a new floodgate of tears, and I hid behind Brother Lu. Mom walked in first and hugged him, then looked at me with a weak smile. Her eyes were swollen9 from her own tears, and I was thankful she had not wept in front of me. And then he was there. He didn t even shake Luther s hand, just nodded as he swept by, coming to me and gathering10 me up into his strong arms, holding me close as he whispered to me, I love you. I love you, and I will love your baby, too.

    Lianget al.[29]illustrated that inhibition of PD-1 can suppress the growth of hepatoma and promote the apoptosis of hepatoma. Increased expression levels of PD-1 were detected in peripheral blood and tumor infiltrating lymphocytes (TILs) of recurrent HCC patients[30]. Blockade of PD-1 on TILs can restore antitumor effects of TILs[31]. However, sPD-1/sPD-L1 was not associated with either PD-L1 expression of tumor cell or the numbers of CD4-positive TILs and CD8-positive TILs[26]. Tumor infiltrating neutrophils as a new target of immunotherapy participate in tumor progression, while the tumor microenvironment(TME) induces impaired antitumor immunity via the modulation of PD-L1 expression on tumor infiltrating neutrophils[32]. PD-L1 was positively associated with expression of CD3 and CD8 in HCC samples[23]. PD-L1 expression on macrophages is also a prognostic factor for HCC patients, and it could activate high levels of CD8(+) cytotoxic T-lymphocyte (CTL) infiltration and immune related gene expression[21].

    Since immune checkpoint molecules are recognized as vital indicators of HCC progress, series of clinical trials with ICIs have been implemented to confirm their potential function for advanced HCC. Nivolumab was approved by the FDA as immunotherapy for advanced stage HCC in 2017[33]. The efficiency of nivolumab was observed in a Phase I/II non-comparative trial (CheckMate 040) of patients with HCC and prior sorafenib treatment[33]. Forty-eight patients were treated with nivolumab in a dose-escalation phase. Then,since nivolumab showed adequate safety and feasibility, 214 patients from 39 sites in 11 countries received nivolumab in a dose-expansion phase. The objective response rates (ORR) of nivolumab were 15% in the dose-escalation phase and 20% in the dose-expansion phase, suggesting that efficacy of nivolumab is not efficient. Twelve of 48 patients had Grade 3/4 treatment-associated adverse events. Although the study was positive in favor of anti-PD-1 treatment, it is worth corroborating the efficacy of nivolumab in a therapeutic schedule. Pre-treatment of sorafenib might potentiate the therapeutic response to subsequent treatment with nivolumab. In real-life experience from three German centers, Grade 3 treatment-associated events occurred in two patients (5.9%), and the partial response rate and stable disease rate in 34 patients with advanced HCC and nivolumab treatment were 11.8% and 23.5% in line with data from the CheckMate 040 trial[34].

    CD19 targeted CAR-T immunotherapy is an expecting therapeutic option that has shown high efficacy in treating hematologic malignancies[55]. Moreover, a great number of CAR-T cell products in solid tumors has also been investigated in preclinical and clinical studies. In 2008, Wilkieet al.[56]reported for the first time that MUC1 targeted CAR-T could significant delay tumor growth in solid tumor[56]. The basic principle of CAR-T cell therapy is the modification of T cells with CARs, so that they can identify tumor cells, and then the retransfusion of these CAR-T cells into the human body to fight against the target cells[57,58]. Several studies have found that GPC3-targeted CAR-T cell therapy can eliminate HCC cells in preclinical research[59-61]. GPC3 is a 70-kDa heparan oncofetal proteoglycans that is located on the tumor cell membrane[62]. It has been demonstrated that GPC3 is detected in HCC tissues with higher expression but not in normal tissues[63]. A Phase I trial (NCT02395250) of 13 Chinese GPC3-positive HCC patients illustrated the safety and preliminary efficacy of GPC3 CAR-T cells in 2017[64]. According to the patient’s tolerance, the preliminary analysis showed that GPC3 targeted CAR-T combined with the lymphodepleting conditioning had a certain efficacy[64]. The pre-clinical studies for dual-targeted CAR-T cells co-expressing GPC3 CARs and GPC3-specific CAR-modified T cells fusing a soluble PD1-CH3 fusion protein showed promising results[60,61].

    Pembrolizumab is also an antibody against PD-1. In a Phase II open-label non-randomized trial(KEYNOTE-224) to assess the efficacy of pembrolizumab as an alternative second-line treatment for HCC patients, the median overall survival (OS) was 12.9 months with a disease control rate of 61% and ORR of 17%[35]. Grade 3 toxicities arose in 25 (24%) of the 104 patients. Hence, pembrolizumab is temporarily approved by the FDA as a second-line therapy for advanced HCC, but it still needs to be verified by the results of more Phase III trials[36]. A Phase III randomized, double-blind trial to further assess the efficacy of pembrolizumab versus placebo in HCC patient is still ongoing (NCT02702401). A Phase II study evaluating camrelizumab for HCC patients with resistance to systemic treatment displayed ORR of 13.8% and acceptable treatment-related adverse events in Chinese advanced HCC patients[37]. In addition to monotherapy, possible multimodality therapeutic options involving ICIs are under investigation. Some research has observed that ICIs of PD-L1 in combination with sorafenib, lenvatinib, rapamycin, and histone deacetylase inhibitor may enhance therapeutic benefit[38-41].

    12. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.

    CTLA-4

    CTLA-4 downregulates activation of T cells by interacting with CD80/CD86 on the surface of DCs[42]. For naive T cell activation, CD28 on T cells provides the second activation signal by binding to CD80/CD86 on DCs[43]. CTLA-4 has a greater affinity for interacting with CD80/CD86 than CD28 so that it interferes in T cell activation[44]. Various single nucleotide polymorphisms (SNP) in CTLA-4 have been well-studied. Several studies observed that polymorphism of CTLA-4 was associated with increased susceptibility to HCC and haplotypes of CTLA-4 may affect the risk of HCC[45-48].

    In 2013, the first CTLA-4 blocking inhibitor in practical HCC treatment was tremelimumab, which displayed promising antitumor activity and acceptable safety[49]. In a clinical trial to validate efficacy of tremelimumab in patients with HCC and HCV infection, partial response rate and disease control rate were 17.6% and 76.4%, respectively[49]. Duffyet al.[50]attempted to combine tremelimumab with ablation as an expected therapeutic option for patients with advanced HCC (NCT01853618) . Five partial responses were observed in 19 patients, with median OS of 12.3 months. Tremelimumab is a human IgG2 monoclonal antibody that blocks the binding of CTLA-4 on the surface of activated T cell[51]. It has been reported that tremelimumab could induce tumor responses in a subset of patients with non-small cell lung cancer and refractory biliary tract cancer[52,53]. Tremelimumab therapy could elevate the amount of T cells in the peripheral blood and TILs, and CD4(+) PD-1(+) cells were more likely to be activated by tremelimumab[54]. An important adverse effect of tremelimumab is transaminitis, as a high proportion of reversible Grade 3/4 transaminitis was observed in both the above-mentioned studies.

    She climbed with the prince to the tops of high mountains; and although her tender feet bled so that even her steps were marked, she only laughed, and followed him till they could see the clouds beneath them looking like a flock of birds travelling to distant lands

    Preclinical data based on series of solid tumors indicate that dual immune checkpoint blockade is synergistic and leads to higher response rates and improved treatment outcomes compared to monotherapy. Most clinical data suggest that both CTLA-4 and PD-1/PD-L1 blockade a portion of HCC patients. Compared to CTLA-4 blockade, PD-1 and PD-L1 blockade showed relatively higher ORR, which could reach 10%-20%in advanced HCC patients. PD-1/PD-L1 blockade agents were more tolerable and less hepatoxic. Further studies for combined PD-1/PD-L1 and CTLA-4 blockades in HCC treatment are still expected, which may help to mitigate the adverse effects of the treatment. Immune checkpoint blockade in advanced HCC combined with other conventional ablative treatments, such as radiofrequency ablation (RFA) or microwave,TACE, chemotherapy, targeted medicine, or surgery would be the most promising approach for HCC patients. However, for unresectable advanced HCC, it is more appropriate to search for other combination strategies, such as the combination with multi-kinase inhibitors, vaccines, and oncolytic viruses, as well as dual inhibition of two immune checkpoint molecules.

    Based on current evidence, combination therapies with CTLA-4 are now an expected direction for the immunotherapy of advanced HCC patients in the future. A Phase III study (NCT03298451) of durvalumab with or without tremelimumabvs. sorafenib in patients of advanced HCC enrolled about 1,350 patients and explored two treatment schedules. Given the limited data to date, further testing of this combination is ongoing in a Phase II expansion. Most ongoing clinical trials have been designed to assess the efficiency of the combination strategies.

    CAR-T CELL THERAPY

    He stroked its feathers, and told it not to be afraid, for it was quite safe; but as he still felt its heart beating, he put it into a cage, where it soon plucked up courage to twitter and hop4 about

    α-fetoprotein (AFP) has been used not only as a biomarker for surveillance and diagnosis of HCC, but also as a target for immunotherapy[65]. In a clinical trial of 15 HCC patients who were given a subcutaneous injection of AFP-derived peptides, 1 patient had a complete response and the disease stabilized in 8 patients[66]. AFP, an intracellular/secreted protein, can generate AFP peptide-major histocompatibility complex (MHC) complexes as targets for CAR T-cell therapy for solid tumors. Liuet al.[67]detected that AFPtargeted CAR-T cells showed significant antitumor capacity in a mouse model Additionally, AFP-derived vaccines can augment the activity of ICIs, leading to deterioration of HCC.

    The experience from successful clinical studies of hematologic malignancies provides us with the understanding that, although selection of the specific antigen to avoid off-target or on-target/off-tumor toxicity is a primary task to be tackled, for HCC, the challenge of CAR-T is the need to ascertain a specific neoantigen and overcome the TME, gut microbiome, and HCC genomic features. Furthermore,the activation, proliferation, and persistence of CAR-T are more important for therapy. In addition,standardization in the production of CAR-T and achieving individualized treatment should be considered.

    No, said Snow-white, I dare not take anything. Are you afraid of poison? said the old woman; look, I will cut the apple in two pieces; you eat the red cheek, and I will eat the white. The apple was so cunningly made that only the red cheek was poisoned. Snow-white longed for the fine apple, and when she saw that the woman ate part of it she could resist no longer, and stretched out her hand and took the poisonous half. But hardly had she a bit of it in her mouth than she fell down dead24. Then the Queen looked at her with a dreadful look, and laughed aloud and said, White as snow, red as blood, black as ebony-wood! this time the dwarfs cannot wake you up again.

    TCR-T CELL THERAPY

    TCR-T cell immunotherapy, as one of the novel and effective antitumor treatment means, has been widely studied in oncotherapy. In 2011, Parkhurstet al.[68]firstly reported that human carcinoembryonic antigen(CEA)-targeted TCR-T cell therapy could induce objective regression of metastatic colorectal cancer[68]. The mechanisms of TCR-T cell therapies are similar to CAR-T immunotherapy. TCR-T therapy also modifies the autologous T cells with TCR, and then retransfusion expands TCR-T cell back into the patient to recognize and eliminate tumor cell, but the mechanisms for identifying antigens are quite different from CAR-T cell therapies[57]. The specific antigens recognized by CAR-T cell are all cell membrane antigens, while TCR-T cell can identify intracellular and cell membrane antigen peptides presented by MHC molecules[69]. In HBVrelated HCC, by performing the high-throughput TCR sequence of TILs in tumor and matched adjacent normal tissues, Linet al.[70]found that the combination of TCR repertoire overlap and TNM stage showed a better prognostic effect for HCC than TNM stage. Qasimet al.[71]firstly reported an HBV-related end-stage HCC case treated with HBV surface antigen as a target for HBV-specific TCR T cell therapy in 2015. In most HBV-related HCC, HBV integrations have been observed and can result in the expression of HCC cells[72].HCC cells comprise fragments of integrated HBV-DNA that encodes peptides, which can be identified by T cells[73]. Another trial was conducted in two advanced HCCs patients who underwent liver transplantation with HCC relapses[74]. During the one-year period of follow up, the volume of 5/6 pulmonary metastases was decreased in one patient receiving HBV-specific TCR T cell therapy[74]. Basic studies of TCR-T cells therapy with specific targets, such as HCV, AFP, and GPC, may be a promising immunotherapy strategy for HCC in the future[75-77]. With TCR-T immunotherapy, the efficacy and side effects seem to mainly depend on the quality of the specific target and the TCR structure. The primary challenge is the discovery of new targets,particularly in the promising field of neoantigens. However, it should be emphasized that neoantigens may be expressed on a subset of tumor cells due to heterogeneity of tumor cell; otherwise, it may cause immune escape.

    DENDRITIC CELL VACCINE

    DCs are powerful antigen-presenting cells that can stimulate T cells to induce antitumor activity. The infiltration of DCs in tumor tissue was closely associated to the improved clinical prognosis in HCC patients[78,79]. In 2002, Ladhamset al.[80]firstly reported two patients with end-stage HCC treated with autologous DCs vaccination co-cultured with autologous HCC antigens. The efficacy of DC vaccination loaded with tumor antigens from different sources has been investigated in clinical studies. Leeet al.[81]reported a trial which enrolled 31 advanced HCC patients receiving DC vaccine pulsed with autologous tumor lysates in 2005. They reported that rates of partial response and stable disease were 12.9% and 54.8%,respectively. A Phase II clinical trial reported disease control rate was 28% for advanced HCC patients with DC vaccination pulsed HepG2 lysate[82]. In another study of note, El Ansaryet al.[83], also using DC vaccine pulsed with HepG2 lysate, showed that DC vaccination could partially improve survival outcome. DC vaccination loaded with autologous tumor lysates or ex vivo HepG2 cell lysate were feasible and effective.

    However, the efficacy of DCs vaccination pulsed with tumor cell lysate is not satisfactory, and thus the use of specific antigen-modified DC vaccination has been attempted. Kakumuet al.[84]suggested that the depressed function of DCs is associated with pathogenesis of HCC with HBV or HCV infection. Several preclinical studies indicated that DCs infected with AFP or HBV antigen or both were effective strategies to enhance efficacy of DC-based vaccine[85-87]. GPC3-modified DCs were potent in inducing T cell proliferation and interferon (IFN)-y production[88]. Tadaet al.[89]reported a clinical effect was observed in one of the five patients receiving DC vaccination pulsed with AFP, GPC3, and MAGE-1 fusion proteins in 2012.Subsequently, a large sample study confirmed that the median time of progression of HCC patients with DC vaccination pulsed with AFP, GPC3 and MAGE-1 fusion proteins was longer than the control group(36.6 monthsvs. 11.8 months)[90].

    32. He G, Zhang H, Zhou J, Wang B, Chen Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141.

    However, the maturation of DC was closely associated with efficacy of DC immunotherapy. The stimulatory capacity of dendritic cells from HCC patients was significantly lower than dendritic cells from liver cirrhosis tissue and normal samples[95]. Meanwhile, the numbers of CD83-positive DCs in HCC specimens were significantly lower compared with liver cirrhosis samples[96]. Therefore, it is very important to improve the maturation of DC, increase antigen source, and depress TME. Various stimuli, such as tumor necrosis factor alpha, lipopolysaccharide, IFN gamma, CD40-ligand, PEG10, IL-12, EpCAM, and HCA661, can significantly increase the stimulatory capacity of DCs[97-102]. Tumor endothelial marker 8 modified DCs could stimulate antitumor immunity by disrupting tumor vasculature, and DCs loaded with specific peptide, such as FoxM1,could significantly inhibit tumor growth and metastasis[103,104]. In addition, RFA can create an antigenic source with stimuli appropriate for maturation of DCs[105]. Regulatory T cells, producing immunosuppressive cytokine IL-10, were concentrated within HCC tissue and were inducted by local TME to interfere the differentiation and maturation of DC[7]. To overcome the immunosuppressive TME, Huet al.[106]introduced a promising vaccine candidate, which combine the DC/tumor cell fusion vaccine with nanoparticles of folate-modified chitosan carrying interferon-induced protein-10, which could effectively inhibit tumor cell proliferation and significantly reduce myeloid-derived suppressor cells in mouse immune organs.

    CIK/DC-CIK

    CIK are a subset of non-MHC-restricted T lymphocytes with immune modulatory effects and a crucial role in anti-tumor immunotherapy[107]. Several studies suggested that CIK cells co-cultured with DCs can significantly enhance antitumor efficiency[108,109]. Qiuet al.[110]reported that alpha-Gal epitope-pulsed DCCIK therapy remarkably prolonged the survival of patients with stage III primary HCC as compared to the controls (17.1 monthsvs. 10.1 months). In a retrospective study from 45 patients with metastatic HCC,median OS of DC-CIK immunotherapy plus ablation (32 months) or ablation (17.5 months) was higher than untreated group (3 months)[111]. In a propensity score-matched analysis, autologous CIK immunotherapy showed significantly longer RFS than the control group[112]. After 5-year follow-up, CIK immunotherapy show a significant reduction in the risk of recurrence or death[113]. The combination therapies DC-CIK with other therapeutic options, such as TACE, could improve the antitumor efficacy. Guoet al.[114]reported that DC-CIK therapy combined with TACE can improve the PFS but not the OS outcomes. However, TACE plus DC-CIK therapy for HCC patients is superior to TACE alone in improving median OS and PFS in a metaanalysis[115]. Zhouet al.[116]analyzed that clinical benefit rate of sorafenib combined with DC-CIK is higher than oral administration of sorafenib (88.6%vs. 41.9%) in a meta-analysis.

    To enhance the therapeutic efficacy of CIK cells, several pre-clinical studies suggested that co-culture of modified DCs, such as IL24-modified DCs, AFP-modified DCs, and GPC3-modified DCs, with CIKs can significantly promote CIKs differentiation and enhance lytic activity of CIK cells[117-119]. They provided a promising DC-CIK vaccine candidate for further clinical trials of HCC patients. Indeed, CIK or DC-CIK immunotherapies from autologous or allogeneic donors have already been extensively used in solid tumor patients. In our clinical center, we have experience with more than 100 gastric cancer patients with DC-CIK immunotherapy and have found that treatment outcomes were effective, safe, and feasible for gastric cancer patients. The standardization in the preparation and criteria of indication are progressing; several clinical trials are registered and ongoing. CIK or DC-CIK immunotherapies, combined with other antitumor agents,should be considered.

    CONCLUSION AND OUTLOOK

    Immunotherapies appear to be a promising treatment for advanced HCC. Multiple prospective studies are attempting to validate the therapy outcomes with PD-1/PD-L1 and/or CTLA-4 blockade. However, only a small proportion of HCC patients effectively respond to immunotherapies and much research is still needed. One of the future directions for immunotherapies is combination therapies with other ICIs, TKIs,vaccines, and oncolytic viruses, as well as conventional treatments in various stages of patients to improve the antitumor efficacy. In addition, it is the important to research how to elevate immunotherapy efficacy and ascertain the biomarkers of predictive therapeutic response to immunotherapy. For example, TMB has been used in several tumor types to predict therapeutic response to anti-PD-1 therapy. In the future, we expect to identify more predictive biomarker subsets which can be used to accurately evaluate the efficacy of immunotherapy.

    Aikido, my teacher had said again and again, is the art of reconciliation11. Whoever has the mind to fight has broken his connection with the universe. If you try to dominate people, you re already defeated. We study how to resolve conflict, not how to start it.

    CAR-T technology and its application has been hailed as a scientific breakthrough in the field of hematological tumors. Application of CAR-T therapy and TCR to treat HCC is expected to be a promising therapeutic method. The crucial challenge is the need to identify specific antigens; overcome the TME, gut microbiome,and HCC genomic features; and guard against adverse effects. Furthermore, the activation, proliferation,and persistence of CAR-T immunotherapy should be considered with the outcomes of treatments for HCC.In addition, standardization in the production of CAR-T and achieving individualized treatment should be considered.

    Different modifications of DC vaccine or DC-CIK therapy, such as selection of specific antigen targets and appropriate immunologic adjuvant, may elevate the effectiveness and safety in further studies. Dendritic cells lead to an increase in the naturally occurring neoantigen-specific immune response as well as the diversity of neoantigens. The combination of DC vaccination with other immunotherapies, e.g., TCR-T, may be a novel treatment modality in the future.

    There were seven of them, but one of them was flawed4. It looked as good as others, almost the size of a tennis ball, nice red fading to light green, but where the stem5 had been there was now a break that went straight down into the heart of the seed.

    Because of the heterogeneity of tumor cells and the complexity of immuno-regulatory mechanisms,multimodality therapies based on immunotherapy represent the next step in clinical antitumor efficacy,which will enable advancing the field and improving the outcomes of HCC patients.

    He had not gone far when all of a sudden he saw the church!He soon came to it, or rather to the wide and deep moat which surrounded it without a single bridge by which to cross

    It was in the spring- the season of storms. The sand from thedunes was whirled up in clouds; the sea was rough, and flocks of birds flew like clouds in the storm, screaming across the sand-hills.Shipwreck followed upon shipwreck on the reefs between Old Skagen and the Hunsby dunes.

    DECLARATIONS

    Authors’ contributions

    Planned and designed of the study: Li Y

    Searched the literature and wrote the manuscript, performed revisions, read and approved the final manuscript for publication: Zhang F, Li Y

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    The present study was supported by the National Natural Science Foundation of China (31770537),International S & T Cooperation Program of China (ISTCP) (2015DFA31650); International S & T Cooperation Program of Gansu Province (18YF1WA113).

    Conflicts of interest

    All authors declared that they have no conflicts of interest.

    Ethics approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ? The Author(s) 2020.

    REFERENCE

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

    24. Huang CY, Wang Y, Luo GY, Han F, Li YQ, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother 2017;40:323-33.

    3. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67.

    4. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019;157:1253-63.e2.

    5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.

    6. Desert R, Rohart F, Canal F, Sicard M, Desille M, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18.

    “Come, little sister,” said the other princesses; then they entwined their arms and rose up in a long row to the surface of the water, close by the spot where they knew the prince’s palace stood

    7. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2019;16:617-30.

    After 19 years of marriage, Steve Benson unsettled his wife, Jean, when he announced three years ago that he would no longer eat meat, for ethical12 reasons

    8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.

    9. Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother 2019;20:1135-52.

    10. Administration UFaD. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2017. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm [Last accessed on 16 Jun 2020]

    11. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.

    Clinical trials of PD-1 antibodies combined with other adjuvant therapy, e.g., transarterial chemoembolization(TACE) and selective internal radiation treatment, are currently in progress. In addition, different combination regimens, which depend on understanding of the actual immune mechanisms in the various combinations,could help us select the optimal therapeutic option for advanced HCC.

    13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.

    14. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2018;18:1169-75.

    15. Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, et al. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.Clin Cancer Res 2017;23:7333-9.

    16. Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1)axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12.

    While the Hunt could bring fertile fields, it was seen as a harbinger of death and war, and it was dangerous to be out when the Hunt was a field for one could become a member of the hunt, be hunted by it, or simply die (Berk and Spytma)

    19. Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702.

    18. Long J, Qu T, Pan XF, Tang X, Wan HH, et al. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance. J Cancer Res Ther 2018;14:S1188-92.

    17. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-96.

    20. Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat 2017;49:246-54.

    The only problem with being in this class was that I was surrounded by at-risk students. These were kids who did not do well in school and didn t want to be there most of the time. Their home lives were obviously much different from mine, and they were constantly in trouble with the school and the law.

    21. Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 2018;119:80-8.

    22. Chang H, Jung W, Kim A, Kim HK, Kim WB, et al. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. Apmis 2017;125:690-8.

    23. Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res 2016;4:419-30.

    2. Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391.

    25. Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015;50:65-75.

    26. Chang B, Huang T, Wei H, Shen L, Zhu D, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:353-63.

    27. Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One 2014;9:e95870.

    28. Li N, Zhou Z, Li F, Sang J, Han Q, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 2017;8:46020-33.

    When the King heard that he had to thank him alone for the victory, he raised him higher than anyone else in rank, gave him great treasures and made him the first in the kingdom

    29. Liang L, Ge K, Zhang F, Ge Y. The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cell Mol Biol Lett 2018;23:58.

    30. Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma. Int Immunopharmacol 2016;41:35-41.

    31. Liu F, Zeng G, Zhou S, He X, Sun N, et al. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBVrelated hepatocellular carcinoma. Bull Cancer 2018;105:493-501.

    DCs pulsed with Hsp70 peptide and OK-432 can enhance efficacy of vaccine inducing T cell proliferation and CTL response[91,92]. In a clinical trial using Hsp70-DC vaccination, 2/12 patients demonstrated complete response and 5/12 patients demonstrated stable disease[93]. In our previous meta-analysis, we concluded DCbased therapy could prolong the median progression free survival (PFS) time and median OS time[94].

    33. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.

    34. Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9.

    35. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.

    36. Marquardt JU, Saborowski A, Czauderna C, Vogel A. The changing landscape of systemic treatment of advanced hepatocellular carcinoma: new targeted agents and immunotherapies. Target Oncol 2019;14:115-23.

    37. Qin SK, Ren ZG, Meng ZQ, Chen ZD, Chai XL, et al. A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol 2018;29:viii719-20.

    38. Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 2019;68:379-93.

    39. Li H, Li X, Liu S, Guo L, Zhang B, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 2017;66:1920-33.

    40. Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer 2014;134:319-31.

    41. Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018;109:3993-4002.

    42. Butty V, Roy M, Sabeti P, Besse W, Benoist C, et al. Signatures of strong population differentiation shape extended haplotypes across the human CD28, CTLA4, and ICOS costimulatory genes. Proc Natl Acad Sci USA 2007;104:570-5.

    43. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity 2016;44:973-88.

    44. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol 2008;29:272-9.

    45. Yang J, Liu J, Chen Y, Tang W, Liu C, et al. Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: a case-control study. Medicine (Baltimore) 2019;98:e16266.

    46. Wang C, Liu W, Zhao L, Dong Z. Association of cytotoxic T-lymphocyte antigen-4 + 49A/G gene polymorphism with hepatocellular carcinoma risk in Chinese. J Cancer Res Ther 2018;14:S1117-20.

    47. Hu L, Liu J, Chen X, Zhang Y, Liu L, et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infectionrelated cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 2010;71:888-91.

    48. Gu X, Qi P, Zhou F, Ji Q, Wang H, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71:83-7.

    49. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.

    50. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.

    51. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.

    52. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308.

    53. Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 2019;69:2048-60.

    54. Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:599-608.

    55. Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma:current status and perspectives. Leukemia 2019;33:2767-78.

    56. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-9.

    57. Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol 2019;10:2250.

    58. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423-31.

    59. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.Clin Cancer Res 2014;20:6418-28.

    60. Chen C, Li K, Jiang H, Song F, Gao H, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66:475-89.

    61. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.

    62. Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev 2018;38:741-67.

    63. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, et al. Glypican 3 expression in human nonneoplastic, preneoplastic,and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008;129:899-906.

    64. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3 + hepatocellular carcinoma (r/r GPC3 + HCC). J Clin Oncol 2017;35:3049.

    65. He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy 2014;6:725-36.

    66. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, et al. Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 2017;152:1395-406.e10.

    67. Liu H, Xu Y, Xiang J, Long L, Green S, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer.Clin Cancer Res 2017;23:478-88.

    68. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.

    69. Xu Y, Yang Z, Horan LH, Zhang P, Liu L, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov 2018;4:62.

    70. Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, et al. T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. Cancer Med 2018;7:3755-62.

    71. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.

    72. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286:533-5.

    73. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.

    74. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.

    75. Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304.

    76. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology 2018;68:574-89.

    77. Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 2015;149:1042-52.

    78. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003;50:1281-4.

    79. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:293-301.

    80. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.

    81. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysatepulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.

    82. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.

    83. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 2013;139:39-48.

    84. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000;15:431-6.

    85. Tan XH, Zhu Q, Liu C, Liu XL, Shao XT, et al. Immunization with dendritic cells infected with human AFP adenovirus vector effectively elicits immunity against mouse hepatocellular carcinomas. Zhonghua Zhong Liu Za Zhi 2006;28:13-6.

    86. Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum Immunol 2010;71:255-62.

    87. Shi M, Qian S, Chen WW, Zhang H, Zhang B, et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBVassociated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol 2007;147:277-86.

    88. Guo DW, Zhang SY, Hou XZ, Li HW, Jiang XF, et al. Glypican3 in genetically modified human monocyte-derived dendritic cells induced specific cytotoxity against glypican3 overexpressing human hepatocellular carcinoma cells in vitro. Saudi Med J 2008;29:1235-40.

    89. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601-9.

    90. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.

    91. Ge C, Xing Y, Wang Q, Xiao W, Lu Y, et al. Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432. Int Immunopharmacol 2011;11:2200-7.

    92. Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011;163:165-77.

    93. Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, et al. Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother 2015;64:1047-56.

    94. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 2018;20:975-89.

    95. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999;31:323-31.

    96. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148:49-57.

    97. Iwashita Y, Goto S, Tahara K, Kawano K, Chen CL, et al. Potent stimuli combined with lipopolysaccaride and IFNgamma may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells. Cancer Biother Radiopharm 2003;18:1-6.

    98. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008;48:157-68.

    99. Chan RC, Pang XW, Wang YD, Chen WF, Xie Y. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer 2004;90:1636-43.

    100. Peng W, Zhao G, Ma Y, Yu H, Wang X. Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo. Vaccine 2011;29:3501-6.

    101. Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int 2014;34:447-61.

    102. Choi YJ, Park SJ, Park YS, Park HS, Yang KM, et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells. PLoS One 2018;13:e0190638.

    103. Yang X, Zhu H, Hu Z. Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth. Vaccine 2010;28:7130-5.

    104. Su H, Li B, Zheng L, Wang H, Zhang L. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Oncotarget 2016;7:48401-11.

    105. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008;31:271-82.

    106. Hu Z, Chen J, Zhou S, Yang N, Duan S, et al. Mouse IP-10 gene delivered by folate-modified chitosan nanoparticles and dendritic/tumor cells fusion vaccine effectively inhibit the growth of hepatocellular carcinoma in mice. Theranostics 2017;7:1942-52.

    107. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.

    108. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice. Immunol Invest 2016;45:553-65.

    109. Chen BA, Li M, Sun ZY, Li CP, Gao C, et al. Killing activity in DC and CIK co-culture against hepatocarcinoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:543-6.

    110. Qiu Y, Xu MB, Yun MM, Wang YZ, Zhang RM, et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011;17:5260-6.

    111. Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013;19:3473-80.

    112. Yoon JS, Song BG, Lee JH, Lee HY, Kim SW, et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:a propensity score-matched analysis of real-world data. BMC Cancer 2019;19:523.

    113. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 2019;68:23-32.

    114. Guo W, Liu L, Wu D. Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao 2014;34:674-8.

    115. He G, Zheng C, Huo H, Zhang H, Zhu Z, et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 2016;40:436-42.

    116. Zhou Z, Qin H, Weng L, Ni Y. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma. J Buon 2019;24:615-21.

    117. Gonzalez-Carmona MA, Marten A, Hoffmann P, Schneider C, Sievers E, et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 2006;26:369-79.

    118. Yu X, Xia W, Zhang T, Wang H, Xie Y, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokineinduced killer cells to hepatocellular carcinoma cells. Int J Hematol 2010;92:276-82.

    119. Wang Y, Wang Y, Mu H, Liu T, Chen X, et al. Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells. Mol Med Rep 2015;11:3361-7.

    av片东京热男人的天堂| 精品第一国产精品| 亚洲一区中文字幕在线| 亚洲精品一区蜜桃| 伦理电影大哥的女人| 18在线观看网站| 日韩av免费高清视频| 久久精品国产综合久久久| 免费看av在线观看网站| 欧美黄色片欧美黄色片| 青草久久国产| 中文字幕最新亚洲高清| 久久久久网色| 久久国产精品男人的天堂亚洲| 久久久久国产网址| 日韩伦理黄色片| 青青草视频在线视频观看| 国产精品免费视频内射| 日韩欧美一区视频在线观看| 亚洲一区二区三区欧美精品| av天堂久久9| 水蜜桃什么品种好| 精品视频人人做人人爽| 一级片免费观看大全| 亚洲国产欧美在线一区| 日韩免费高清中文字幕av| 日韩制服丝袜自拍偷拍| 欧美日韩综合久久久久久| 免费在线观看黄色视频的| 欧美日韩视频高清一区二区三区二| 日韩 亚洲 欧美在线| 免费少妇av软件| 99国产综合亚洲精品| 少妇人妻 视频| 啦啦啦在线免费观看视频4| 国产无遮挡羞羞视频在线观看| 久久久欧美国产精品| 边亲边吃奶的免费视频| 搡老乐熟女国产| 最近2019中文字幕mv第一页| 久久这里有精品视频免费| 亚洲av欧美aⅴ国产| 成年女人毛片免费观看观看9 | 肉色欧美久久久久久久蜜桃| 桃花免费在线播放| 亚洲av免费高清在线观看| 精品亚洲成国产av| 亚洲第一区二区三区不卡| 久久久久久伊人网av| 亚洲成人手机| av在线老鸭窝| 边亲边吃奶的免费视频| 国产一区二区 视频在线| 韩国高清视频一区二区三区| 成人亚洲精品一区在线观看| 菩萨蛮人人尽说江南好唐韦庄| 国产成人免费无遮挡视频| 晚上一个人看的免费电影| 看免费成人av毛片| 少妇人妻 视频| 亚洲婷婷狠狠爱综合网| 欧美97在线视频| 精品国产一区二区三区久久久樱花| 一区二区av电影网| 欧美 亚洲 国产 日韩一| 91成人精品电影| 国产精品av久久久久免费| 极品人妻少妇av视频| 精品久久久精品久久久| 亚洲欧美色中文字幕在线| 肉色欧美久久久久久久蜜桃| 91久久精品国产一区二区三区| 最近2019中文字幕mv第一页| 亚洲男人天堂网一区| 只有这里有精品99| 亚洲,一卡二卡三卡| 久久久久久人妻| 国产白丝娇喘喷水9色精品| 国产国语露脸激情在线看| 国产成人免费无遮挡视频| 黑人巨大精品欧美一区二区蜜桃| 免费女性裸体啪啪无遮挡网站| 中国三级夫妇交换| 女性被躁到高潮视频| 日韩视频在线欧美| 国产综合精华液| 国产日韩欧美视频二区| 九草在线视频观看| 18禁裸乳无遮挡动漫免费视频| 一本久久精品| 男人添女人高潮全过程视频| 免费高清在线观看视频在线观看| 国产片内射在线| 性色av一级| 99re6热这里在线精品视频| 国产精品一国产av| 国产高清国产精品国产三级| 一二三四在线观看免费中文在| 80岁老熟妇乱子伦牲交| 免费观看a级毛片全部| 久久97久久精品| 久久久久久人妻| 捣出白浆h1v1| 99久久中文字幕三级久久日本| 一本大道久久a久久精品| 午夜福利视频在线观看免费| 亚洲精品自拍成人| 黑人猛操日本美女一级片| 国产日韩欧美视频二区| 黑丝袜美女国产一区| 国产精品人妻久久久影院| 男人爽女人下面视频在线观看| 欧美97在线视频| 美女大奶头黄色视频| 青春草亚洲视频在线观看| 成人二区视频| 亚洲成色77777| 午夜av观看不卡| 黄色毛片三级朝国网站| 国产色婷婷99| 成人手机av| 我的亚洲天堂| 亚洲第一av免费看| 91aial.com中文字幕在线观看| 一区二区三区四区激情视频| 在线观看一区二区三区激情| 黄片无遮挡物在线观看| 卡戴珊不雅视频在线播放| 十八禁高潮呻吟视频| 亚洲欧美一区二区三区黑人 | 欧美+日韩+精品| 久久精品国产自在天天线| 国产高清国产精品国产三级| 黄色视频在线播放观看不卡| 国产欧美日韩一区二区三区在线| 又大又黄又爽视频免费| 日本猛色少妇xxxxx猛交久久| 中文字幕精品免费在线观看视频| 男女午夜视频在线观看| 国产免费现黄频在线看| 日韩中字成人| 久久97久久精品| 狂野欧美激情性bbbbbb| 波多野结衣av一区二区av| 久久久久久久久久久免费av| 街头女战士在线观看网站| 黑人猛操日本美女一级片| 99久国产av精品国产电影| 亚洲av在线观看美女高潮| 伦精品一区二区三区| 边亲边吃奶的免费视频| 日韩三级伦理在线观看| 午夜福利视频精品| 国产一级毛片在线| 午夜免费观看性视频| 国产av精品麻豆| 国产熟女午夜一区二区三区| 丰满乱子伦码专区| 最近手机中文字幕大全| 三上悠亚av全集在线观看| 18禁国产床啪视频网站| 免费观看在线日韩| 日本vs欧美在线观看视频| 91精品国产国语对白视频| 性色av一级| 亚洲精华国产精华液的使用体验| 久久久久久久久久久久大奶| 777米奇影视久久| 一区二区三区四区激情视频| 人妻系列 视频| 在线观看人妻少妇| 国产精品一区二区在线观看99| 黄片无遮挡物在线观看| 在线观看国产h片| 亚洲五月色婷婷综合| 免费少妇av软件| 精品国产乱码久久久久久男人| 国产欧美日韩综合在线一区二区| 成人18禁高潮啪啪吃奶动态图| 日韩 亚洲 欧美在线| 巨乳人妻的诱惑在线观看| 丝袜美腿诱惑在线| 最黄视频免费看| www.熟女人妻精品国产| 男人爽女人下面视频在线观看| 巨乳人妻的诱惑在线观看| 一级毛片黄色毛片免费观看视频| 亚洲欧洲国产日韩| 黑人欧美特级aaaaaa片| 一级黄片播放器| 成年女人在线观看亚洲视频| 成人毛片a级毛片在线播放| 少妇的丰满在线观看| 男男h啪啪无遮挡| 如何舔出高潮| 国产在线视频一区二区| 日韩中字成人| 久久精品久久精品一区二区三区| 少妇人妻精品综合一区二区| 国产亚洲精品第一综合不卡| 女人久久www免费人成看片| 波多野结衣一区麻豆| 免费av中文字幕在线| 欧美日韩av久久| 伊人久久国产一区二区| 亚洲人成77777在线视频| 久久99蜜桃精品久久| 多毛熟女@视频| 免费黄色在线免费观看| 国产不卡av网站在线观看| 久久免费观看电影| 免费久久久久久久精品成人欧美视频| 欧美 亚洲 国产 日韩一| 免费少妇av软件| 高清黄色对白视频在线免费看| 少妇人妻 视频| 精品卡一卡二卡四卡免费| 黑人巨大精品欧美一区二区蜜桃| 波野结衣二区三区在线| 一区二区av电影网| 精品国产国语对白av| 免费黄网站久久成人精品| 国产白丝娇喘喷水9色精品| 精品一区二区三区四区五区乱码 | 日韩视频在线欧美| 国产成人精品无人区| 在线观看三级黄色| 最近2019中文字幕mv第一页| 18+在线观看网站| 午夜av观看不卡| 91精品伊人久久大香线蕉| 老女人水多毛片| 久久免费观看电影| 久久ye,这里只有精品| 国产一级毛片在线| 大陆偷拍与自拍| 夫妻午夜视频| 日韩中文字幕欧美一区二区 | 国产精品99久久99久久久不卡 | 免费高清在线观看日韩| 久久久久国产一级毛片高清牌| 亚洲国产精品成人久久小说| 一区福利在线观看| 亚洲美女黄色视频免费看| xxxhd国产人妻xxx| 亚洲精品在线美女| 黄片小视频在线播放| 男人操女人黄网站| 王馨瑶露胸无遮挡在线观看| 午夜精品国产一区二区电影| 成人免费观看视频高清| 少妇的丰满在线观看| 亚洲欧美一区二区三区国产| 欧美老熟妇乱子伦牲交| 1024视频免费在线观看| 丰满乱子伦码专区| 久久人人爽人人片av| 欧美人与善性xxx| 最黄视频免费看| 人妻人人澡人人爽人人| 亚洲人成网站在线观看播放| 男女啪啪激烈高潮av片| 欧美日韩视频高清一区二区三区二| 九九爱精品视频在线观看| 在线天堂最新版资源| 久久久精品94久久精品| 亚洲精品国产av蜜桃| 人体艺术视频欧美日本| 中文精品一卡2卡3卡4更新| 亚洲av免费高清在线观看| a级片在线免费高清观看视频| 亚洲天堂av无毛| 亚洲婷婷狠狠爱综合网| 久久久久久久亚洲中文字幕| 亚洲激情五月婷婷啪啪| 国产精品女同一区二区软件| 亚洲美女搞黄在线观看| 欧美日韩一区二区视频在线观看视频在线| 国产激情久久老熟女| 欧美日韩亚洲高清精品| 中文字幕另类日韩欧美亚洲嫩草| √禁漫天堂资源中文www| 国产精品久久久久久精品古装| 国产成人精品在线电影| 国产精品亚洲av一区麻豆 | 亚洲三区欧美一区| 久久久久国产网址| 色婷婷av一区二区三区视频| av不卡在线播放| 国产精品香港三级国产av潘金莲 | 国产日韩欧美在线精品| 亚洲av国产av综合av卡| 一二三四中文在线观看免费高清| 天天影视国产精品| 欧美日韩视频精品一区| 久久 成人 亚洲| 午夜影院在线不卡| 免费人妻精品一区二区三区视频| 国产av国产精品国产| 熟妇人妻不卡中文字幕| 在线天堂最新版资源| 午夜激情久久久久久久| 亚洲精品成人av观看孕妇| 精品人妻熟女毛片av久久网站| 99久久中文字幕三级久久日本| 国产 精品1| 国产淫语在线视频| 超色免费av| 亚洲,一卡二卡三卡| 男人添女人高潮全过程视频| 电影成人av| 色视频在线一区二区三区| 香蕉精品网在线| 免费高清在线观看日韩| 大片电影免费在线观看免费| 亚洲欧美日韩另类电影网站| 99re6热这里在线精品视频| 久久久久精品久久久久真实原创| 久久综合国产亚洲精品| 女的被弄到高潮叫床怎么办| 欧美老熟妇乱子伦牲交| 少妇被粗大猛烈的视频| 免费观看无遮挡的男女| 久久精品国产鲁丝片午夜精品| 男女免费视频国产| 亚洲av电影在线观看一区二区三区| 青春草国产在线视频| 成年人免费黄色播放视频| 99热网站在线观看| av电影中文网址| 午夜免费观看性视频| 男人操女人黄网站| 欧美日韩国产mv在线观看视频| 国产日韩欧美亚洲二区| 国产免费福利视频在线观看| 欧美中文综合在线视频| 日韩中文字幕欧美一区二区 | 免费黄色在线免费观看| 久久久久精品人妻al黑| 成人国语在线视频| a 毛片基地| 黄片小视频在线播放| 亚洲av成人精品一二三区| 夜夜骑夜夜射夜夜干| 午夜福利一区二区在线看| 午夜免费鲁丝| 美女视频免费永久观看网站| 国产av码专区亚洲av| 熟女少妇亚洲综合色aaa.| 丰满饥渴人妻一区二区三| 国产精品.久久久| 日韩一卡2卡3卡4卡2021年| av不卡在线播放| 考比视频在线观看| 亚洲美女黄色视频免费看| 两个人看的免费小视频| 天天躁夜夜躁狠狠躁躁| 日本-黄色视频高清免费观看| 国产一区二区 视频在线| 久久人人97超碰香蕉20202| 精品福利永久在线观看| 久久午夜综合久久蜜桃| 女的被弄到高潮叫床怎么办| 免费观看av网站的网址| 午夜久久久在线观看| 黄色 视频免费看| 人体艺术视频欧美日本| 亚洲精品国产一区二区精华液| 欧美亚洲日本最大视频资源| 中文字幕另类日韩欧美亚洲嫩草| 人人澡人人妻人| www.自偷自拍.com| 日韩一本色道免费dvd| 嫩草影院入口| 久久这里有精品视频免费| 亚洲美女视频黄频| 99久国产av精品国产电影| 亚洲精品美女久久久久99蜜臀 | 亚洲国产精品999| 亚洲欧洲国产日韩| 一二三四在线观看免费中文在| 亚洲经典国产精华液单| 在线观看国产h片| 涩涩av久久男人的天堂| 超色免费av| 午夜福利影视在线免费观看| 亚洲国产精品999| 爱豆传媒免费全集在线观看| 少妇熟女欧美另类| 老司机影院毛片| 国产亚洲最大av| 九九爱精品视频在线观看| 伊人亚洲综合成人网| 91精品国产国语对白视频| 国产午夜精品一二区理论片| 国产精品偷伦视频观看了| 一二三四中文在线观看免费高清| 精品一品国产午夜福利视频| 青草久久国产| 我要看黄色一级片免费的| 高清视频免费观看一区二区| 少妇人妻久久综合中文| 欧美精品亚洲一区二区| 色网站视频免费| 一级毛片电影观看| 日日啪夜夜爽| 亚洲精品日韩在线中文字幕| 一本大道久久a久久精品| 18禁国产床啪视频网站| 爱豆传媒免费全集在线观看| 亚洲国产成人一精品久久久| 欧美精品人与动牲交sv欧美| 亚洲 欧美一区二区三区| 欧美97在线视频| 日本av免费视频播放| 国产片特级美女逼逼视频| 成年人免费黄色播放视频| 性少妇av在线| 免费看av在线观看网站| 欧美xxⅹ黑人| 久久97久久精品| 黄片小视频在线播放| 亚洲国产欧美在线一区| 成年av动漫网址| 只有这里有精品99| 国产片特级美女逼逼视频| 久久久久国产网址| 久久影院123| 人妻 亚洲 视频| 国产97色在线日韩免费| 欧美成人精品欧美一级黄| 只有这里有精品99| 午夜激情av网站| av.在线天堂| 一二三四中文在线观看免费高清| 另类亚洲欧美激情| 亚洲国产欧美在线一区| 蜜桃国产av成人99| 亚洲精品日韩在线中文字幕| 国产片特级美女逼逼视频| 波野结衣二区三区在线| 国产av国产精品国产| 18禁国产床啪视频网站| 少妇人妻久久综合中文| 久热久热在线精品观看| 91国产中文字幕| 国产成人免费无遮挡视频| 中文字幕人妻丝袜一区二区 | xxxhd国产人妻xxx| 青春草视频在线免费观看| 国产黄频视频在线观看| 精品少妇一区二区三区视频日本电影 | 成人亚洲欧美一区二区av| 啦啦啦中文免费视频观看日本| 国产又色又爽无遮挡免| 久久久久视频综合| 免费黄网站久久成人精品| 观看av在线不卡| 亚洲av综合色区一区| 汤姆久久久久久久影院中文字幕| 久久久久网色| 中文字幕人妻丝袜制服| 亚洲婷婷狠狠爱综合网| 精品酒店卫生间| 久久青草综合色| 亚洲,欧美,日韩| 伦理电影免费视频| 成年女人在线观看亚洲视频| av免费在线看不卡| 精品亚洲乱码少妇综合久久| 街头女战士在线观看网站| 最近的中文字幕免费完整| 男女下面插进去视频免费观看| 日韩免费高清中文字幕av| 国产av精品麻豆| 99九九在线精品视频| 国产精品一区二区在线观看99| 黄色毛片三级朝国网站| 99国产精品免费福利视频| 观看美女的网站| 久久亚洲国产成人精品v| 久久ye,这里只有精品| 久久婷婷青草| 亚洲内射少妇av| 秋霞伦理黄片| 久久久国产一区二区| 日韩电影二区| 大片电影免费在线观看免费| 少妇精品久久久久久久| 最近最新中文字幕免费大全7| 伊人久久国产一区二区| 国产欧美日韩综合在线一区二区| 欧美日韩亚洲高清精品| av免费观看日本| 亚洲欧洲精品一区二区精品久久久 | av又黄又爽大尺度在线免费看| 高清在线视频一区二区三区| 亚洲国产av新网站| 精品亚洲乱码少妇综合久久| 最黄视频免费看| 女人被躁到高潮嗷嗷叫费观| 哪个播放器可以免费观看大片| 国产一级毛片在线| 男人操女人黄网站| 久久久久久免费高清国产稀缺| 国产极品天堂在线| 狂野欧美激情性bbbbbb| 91午夜精品亚洲一区二区三区| 免费在线观看视频国产中文字幕亚洲 | 日本黄色日本黄色录像| 国产精品女同一区二区软件| 人妻一区二区av| 在线观看美女被高潮喷水网站| 午夜福利,免费看| 中国国产av一级| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 成年人午夜在线观看视频| 免费观看av网站的网址| 又黄又粗又硬又大视频| 精品国产露脸久久av麻豆| 美国免费a级毛片| 欧美xxⅹ黑人| 国产精品久久久久久精品电影小说| 高清黄色对白视频在线免费看| 人妻少妇偷人精品九色| av网站免费在线观看视频| 亚洲av免费高清在线观看| 大陆偷拍与自拍| 婷婷色综合www| 久久久久久久久久人人人人人人| 卡戴珊不雅视频在线播放| 国产在线免费精品| 99久久综合免费| 波野结衣二区三区在线| 在线观看免费高清a一片| 老司机影院毛片| av电影中文网址| 久久精品国产亚洲av高清一级| 亚洲国产精品成人久久小说| 伊人亚洲综合成人网| 欧美成人午夜精品| 国产一区二区三区av在线| 国产一级毛片在线| 精品国产乱码久久久久久小说| 国产成人欧美| 哪个播放器可以免费观看大片| 晚上一个人看的免费电影| 又大又黄又爽视频免费| 狠狠精品人妻久久久久久综合| 极品人妻少妇av视频| 老女人水多毛片| 亚洲国产av影院在线观看| 伊人久久国产一区二区| 自拍欧美九色日韩亚洲蝌蚪91| 在线观看一区二区三区激情| 老司机福利观看| 丰满的人妻完整版| 国产人伦9x9x在线观看| a级片在线免费高清观看视频| 精品久久久久久久久久免费视频 | 亚洲一卡2卡3卡4卡5卡精品中文| 大型黄色视频在线免费观看| 美女 人体艺术 gogo| 亚洲成人免费av在线播放| 亚洲国产中文字幕在线视频| 午夜免费观看网址| 精品国内亚洲2022精品成人| 美女高潮到喷水免费观看| 精品久久久精品久久久| 男女之事视频高清在线观看| 97人妻天天添夜夜摸| 午夜免费激情av| 欧美日韩亚洲高清精品| 女人精品久久久久毛片| 日韩 欧美 亚洲 中文字幕| 国产av一区在线观看免费| 长腿黑丝高跟| 亚洲av片天天在线观看| 亚洲七黄色美女视频| 久久香蕉精品热| 国产精品美女特级片免费视频播放器 | 男人操女人黄网站| 日韩欧美国产一区二区入口| av片东京热男人的天堂| 啦啦啦免费观看视频1| 黄色丝袜av网址大全| 在线天堂中文资源库| 国产亚洲精品一区二区www| 人成视频在线观看免费观看| 麻豆成人av在线观看| 国产熟女午夜一区二区三区| 精品人妻1区二区| 久久久国产一区二区| 国产精品国产av在线观看| 国产99久久九九免费精品| 成在线人永久免费视频| 欧美不卡视频在线免费观看 | 女性生殖器流出的白浆| 9色porny在线观看| 亚洲成av片中文字幕在线观看| 精品高清国产在线一区| 久久精品国产亚洲av高清一级| 又紧又爽又黄一区二区| 国产熟女午夜一区二区三区| av天堂在线播放| 亚洲avbb在线观看| 亚洲,欧美精品.| 窝窝影院91人妻| 免费女性裸体啪啪无遮挡网站| 国产精品1区2区在线观看.| 久久午夜亚洲精品久久| 涩涩av久久男人的天堂| 夫妻午夜视频| 亚洲精品国产精品久久久不卡| 欧美 亚洲 国产 日韩一|